Impact of hypoalbuminemia on clinical outcomes among patients with obesity treated with ceftriaxone
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.01663-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Kellie Arensman Hannan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Mayo Clinic Health System, Mankato, Minnesota, USA. Hauptthemen laut MEDLINE: Hypoalbuminemia. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The use of ceftriaxone, a highly protein-bound drug, in the setting of hypoalbuminemia may result in suboptimal drug exposure. Patients with obesity also exhibit higher absolute drug clearance. We aimed to evaluate the impact of hypoalbuminemia on clinical success among hospitalized adults with obesity who were treated with ceftriaxone. This retrospective review included adult inpatients with weight >100 kg or body mass index >40 kg/m 2 who received ceftriaxone 2 g intravenously every 12 hours for at least 72 hours. The primary outcome was clinical success, a composite of clinical cure and microbiologic cure. Secondary outcomes included clinical cure, microbiologic cure, length of stay, ICU length of stay, mortality, 30-day readmission, and adverse events. In all, 137 patients were included, 34 of whom had a serum albumin of ≤2.5 g/dL. In a propensity-score-weighted analysis, clinical success was significantly more common among those without hypoalbuminemia (91.2%) as compared to those with hypoalbuminemia (77.8%) ( P = 0.038). Death within 30 days (13.7% vs 0%, P < 0.001) and 30-day readmission (31.6% vs 12.0%, P = 0.008) were more common in the hypoalbuminemia group. In a univariate analysis, serum albumin and indication for ceftriaxone use were found to be predictors of clinical success. Hypoalbuminemia was associated with a lower rate of clinical success among patients with obesity who were treated with ceftriaxone 2 g every 12 hours.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Mayo Clinic Health System, Mankato, Minnesota, USA.
- Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Kellie Arensman Hannan, Christina G Rivera
Zitieren
APA
Arensman Hannan, K., Draper, E., Cole, K. C., Mc Hugh, J., Rivera, C. G., & Abu Saleh, O. (2024). Impact of hypoalbuminemia on clinical outcomes among patients with obesity treated with ceftriaxone. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01663-23
Vancouver
Arensman Hannan K, Draper E, Cole KC, Mc Hugh J, Rivera CG, Abu Saleh O. Impact of hypoalbuminemia on clinical outcomes among patients with obesity treated with ceftriaxone. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.01663-23
BibTeX
@article{ArensmanHannan2024,
author = {Arensman Hannan, Kellie and Draper, Evan and Cole, Kristin C and Mc Hugh, Jack and Rivera, Christina G and Abu Saleh, Omar},
title = {Impact of hypoalbuminemia on clinical outcomes among patients with obesity treated with ceftriaxone},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.01663-23}
}
EUVIMED